The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

Jan 14, 2025 · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...

Feb 6, 2024 · New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.

Jan 14, 2025 · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024...

Jan 15, 2025 · The revised outlook, discussed at the JP Morgan Healthcare Conference 2025 on 14 January, has been attributed to stocking levels and unexpected market dynamics in Q4 2024 in the diabetes...

Jan 14, 2025 · On Tuesday, Eli Lilly and Company (NYSE: LLY) found itself in the spotlight after its stock plummeted 7.67%, or $61.14, dropping to $736.34 at 12:38 PM EST. With a trading volume of 6.66 million shares—far exceeding the average of 3.89 million—Lilly became one of the trending stocks of the day. ... The Q4 2024 revenue estimate of $13.5 ...

Jan 13, 2025 · Analysts expect Eli Lilly’s EPS to climb 107.9% to $13.14 in fiscal 2024, up from $6.32 in 2023. In fiscal 2025, EPS is projected to increase by 82.9% annually to $24.03.

Citing lower-than-expected sales for its weight-loss medicine Zepbound and diabetes treatment Mounjaro, Eli Lilly (NYSE:LLY) revised its fourth-quarter revenue projection downward. Now...

Feb 6, 2024 · Eli Lilly (LLY 2.45%) Q4 2023 Earnings Call Feb 06, 2024, 10:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator

INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025.Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.